New drug cocktail shows promise for lung cancer patients with brain tumors
NCT ID NCT05012254
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus two cycles of chemotherapy as a first treatment for people with advanced lung cancer that has spread to the brain. The study aims to see if this approach can control the cancer in the brain and body. About 71 participants are being enrolled, and the main goal is to measure how many patients have no cancer growth in the brain for at least six months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab (Opdivo) and ipilimumab (Yervoy) plus two cycles of platinum-based chemotherapy
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for lung cancer patients with brain metastases, potentially improving disease control and survival.
- What could go wrong
- This is a small, early-phase (phase 2) trial with only 71 participants, so results may not apply to all patients. The combination of immunotherapy and chemotherapy can cause serious side effects, including immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital 12 De Octubre
Madrid, Madrid, 28041, Spain
-
Hospital Clínico Universitario de Valladolid
Valladolid, Valladolid, 47003, Spain
-
Hospital General Universitario de Valencia
Valencia, Valencia, 46014, Spain
-
Hospital Provincial de Castellón
Castellon, Castellon, 12002, Spain
-
Hospital Universitari Son Llatzer
Palma de Mallorca, Palma de Mallorca, 07198, Spain
-
Hospital Universitari Vall d' Hebron
Barcelona, Barcelona, 08035, Spain
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, Madrid, 28040, Spain
-
Hospital Universitario Insular de Gran canaria
Las Palmas de Gran Canaria, Gran Canaria, 35016, Spain
-
Hospital Universitario La Fe
Valencia, Valencia, 46026, Spain
-
Hospital Universitario Lucus Augusti
Lugo, Lugo, 27003, Spain
-
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, 28222, Spain
-
Hospital Universitario Regional de Málaga
Málaga, Málaga, 29010, Spain
-
Hospital Universitario de Jaén
Jaén, Jaén, 23007, Spain
-
Hospital Universitario de León
León, León, 24071, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, 08041, Spain
-
Hospitalario Universitario A Coruña
A Coruña, La Coruña, 15006, Spain
-
ICO Badalona, Hospital Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
-
ICO Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?